North America Cancer Monoclonal Antibodies Market is estimated to be a USD 10.26 billion market in 2015 and is expected to reach USD 17 billion market by the end of 2020 with a significant growth rate of 10.5%.
Cancer is the leading cause of death currently across the globe. It starts with a single cell genetically transforming normal cell into tumour and is spread gradually to the other cells. The dramatic increases in the number of cancer cases has prompted many pharmaceutical companies to invest in monoclonal antibodies. The practise for curing cancer currently include usage of drugs and chemotherapy which have adverse side effects. This persuade the usage of Monoclonal antibodies.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/north-america-cancer-monoclonal-antibodies-market-187/request-sample
Recent years have seen the emergence of monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer, autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while sparing the healthy cells. Monoclonal antibodies are more effective in treating cancer than their counter parts like drugs or chemotherapy owing to their adverse side effects.
The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, technological innovations in target gene selection and genetic sequencing, monoclonal antibodies ability to target only specific cells, having no side effects compared to its counter parts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having a presence of highly strong products in the pipeline. There are also few restraints for its market entry like high cost, stringent guidelines, long durations required for R&D, clinical trials.
The North America Monoclonal Antibodies are categorised on the basis of application as Breast, Brain, blood, Liver, Hodgkins and Non-Hodgkins lymphoma, leukaemia, colorectal and others. The market is again segmented based on type as chimeric and humanised antibodies, murine antibodies and fully humanized antibodies. The market is again divided into various categories by conjugated cancer therapies as Radoimmunotherapy, ADEPT, Immunoliposome, immunocytokines and others. Based on the geographical region of North America it is segmented into US and Canada.
The major companies in this industry are Amgen, Genmab, Briston Myers squibb, glaxosmithkline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis and Spectrum Pharmaceuticals.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases